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Clinical Utility of Epstein-Barr Virus Viral Load
Monitoring and Risk Factors for Posttransplant
Lymphoproliferative Disorders After Kidney
Transplantation: A Single-Center, 10-Year
Observational Cohort Study
Erica Franceschini, MD,1 Jessica Plessi, MD,1 Stefano Zona,MD,1 Antonella Santoro,MD,1Margherita Digaetano,MD,1
Francesco Fontana, MD,2 Gaetano Alfano, MD,2 Giovanni Guaraldi, MD,3 Patrizia Comoli, MD,4
Francesca Facchini, MD,2 Leonardo Potenza, MD, PhD,5 William Gennari, MD,6 Mauro Codeluppi, MD,1
Mario Luppi, MD, PhD,5 Gianni Cappelli, MD,2 Inge C. Gyssens, MD, PhD,7,8 Cristina Mussini, MD3
Background. Posttransplant lymphoproliferative disease (PTLD) is an important cause of morbidity and mortality in solid
organ transplants. Epstein Barr virus (EBV) plays a major role in PTLD development. Guidelines recommend EBV viral load
(VL) monitoring in high-risk populations in the first year. Methods. Retrospective observational study in all adult patients
who had at least 1 EBV-VL performed in the postkidney transplant (KT) period from January 2005 to December 2014 at
the Policlinico Modena Hospital. We compared patients with negative EBV-DNA to patients with positive EBV-DNA and
we described PTLD developed in the study period.Results.One hundred ninety (36.3%) KT patients of 523 were screened
for EBV-DNA with 796 samples. One hundred twenty-eight (67.4%) of 190 tested patients presented at least 1 positive
sample for EBV. Older age, the use of sirolimus, everolimus, and steroids were associated with EBV-DNA positivity in the
univariate analysis. Nine (1.7%) of 523 patients had PTLD. Incidence rate of PTLD in the KT cohort was 0.19/100 person
year follow-up (95% confidence interval, 0.09-0.37). One of 9 patients developed early PTLD and was a high-risk patient.
Only this PTLD case was positive for EBV. No PTLD case had an EBV-VL superior to 4000 copies/mL. Conclusions.
Our results suggest that the keystone of PTLD diagnosis is the clinical suspicion. Our study suggests that, in line with guide-
lines, EBV-VL assays may be avoided in low-risk patients in the absence of a strong clinical PTLD suspicion without
increasing patients' risk of developing PTLD. This represents a safe and cost-saving clinical strategy for our center.
(Transplantation Direct 2017;3:e182; doi: 10.1097/TXD.0000000000000703. Published online 26 June, 2017.)
Posttransplant lymphoproliferative disease (PTLD) is in-creasingly recognized as an important cause ofmorbidity
and mortality in solid organ transplants.1 Kidney transplant
recipients are at relatively low risk (1-3%).2
Epstein-Barr virus (EBV) is ubiquitous, and about 90% of
theworld adult population have anti-EBVantibodies.3 In Italy,
the seroprevalence in the adult population is 88.4%,4 and
the primary infection usually occurs early in life. Effectively,
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72.7% of Italian children aged 10 years already show EBV
immunity.5 Most EBV infections in immunocompetent hosts
are asymptomatic in children, whereas primary infections in
adults frequently result in infectious mononucleosis.6,7 Over
50% of patients with infectious mononucleosis manifest fever,
lymphadenopathy, and pharyngitis. EBV also plays a role in
the development of nasopharyngeal carcinoma, Burkitt lym-
phoma,6 and PTLD.2 In kidney transplant recipients, PTLD
has shown bimodal patterns of incidence, with peaks in the
first year and then in the later posttransplantation period.8-10
Patient survival after PTLD diagnosis is 64% at 1 year, 48%
at 5 years, and 37% at 10 years.11 The EBV genome is found
in more than 90% of B cell PTLD occurring during the first
year after transplantation, while up to 45% of late onset
PTLD are EBV negative.1,12 The pathogenesis of these disor-
ders is complex and related to EBV ability to transform and
immortalize B lymphocytes, combined with secondary genetic
or epigenetic events that occur during uncontrolled prolifera-
tion.2 Although the role of EBV in EBV-negative PTLD is un-
certain, recent data support the hypothesis that over time,
immune escape occurs in initially EBV-driven lymphoprolifer-
ation, with cellular mutations replacing the functions of EBV
oncogenes.2,13
Due to the impaired immunity after transplant, kidney
transplant recipients are at risk for viral reactivation.14 Indeed,
immunosuppression is associated with EBV, cytomegalovirus
(CMV), β-herpesviruses,15 and polyoma BK reactivation. Po-
tential microbial interactions between viruses have been sug-
gested and canmodify the clinical presentation of infections.14
Kidney Disease: Improving Global Outcomes guidelines16
suggest monitoring high-risk kidney transplants (defined as
donor EBV seropositive and recipient EBV seronegative) for
EBV by nucleic acid testing after transplantation once in the
first week, monthly for the first 3 to 6 months, then every
3 months until the end of the first posttransplant year, and
additionally after treatment for acute rejection. Kidney Dis-
ease: Improving Global Outcomes guidelines recommend re-
ducing immunosuppressive medication in EBV-seronegative
patients with an increasing EBV viral load (VL) and in pa-
tients with EBV disease, including PTLD. The more recent
American Society of Transplantation guidelines2 state that
there are data17 to support quantitative EBV-VL monitoring
for PTLD prevention only in high-risk populations in the first
year. Data to support monitoring in the population at low-
risk for PTLD are lacking.2,16
In contrast with the guidelines, a recent survey published
by the European Study Group of Infections in Compromised
Hosts18 showed that EBV-VL measurements are frequently
used in Europe to guide both the diagnostic workup and
the reduction of immunosuppression in solid organ trans-
plants. EBVmonitoring is routinely used in 86%of the trans-
plant programs; in particular, 38% of renal transplant
centers perform EBV-VL surveillance in all recipients, inde-
pendently from the EBV risk evaluation. Furthermore, 77%
perform preemptive treatments for patients with high-risk
EBV DNAemia levels such as the reduction of immunosup-
pression (50.9%), and the conversion to mammalian target
of rapamaycin inhibitors (mTORi) (30.9%). Up to 14.5%
had used rituximab for this indication and 7.3% reported
the use of immune- adoptive T cell therapy.
EBV DNAemia levels considered significant can vary be-
tween centers.19,20 In our study, the value of 4000 copies/mL
has been chosen based on literature data evaluating such a
threshold as a risk factor for PTLD onset.21
In view of the difference between guidelines and clinical
practice in Europe, the aims of our study were to assess the
clinical utility of EBV-VL monitoring and risk factors for
PTLD in the kidney transplant cohort from Azienda
Ospedaliero-Universitaria (AOU) Policlinico inModena, Italy.
MATERIALS AND METHODS
Study Design
A retrospective, observational, single-center studywas per-
formed in patients in follow-up after kidney transplantation
(KT) from January 1987 to December 2014 in the Clinic of
Nephrology at AOU Policlinico Modena Hospital. All adult
(≥18 years) patients who had at least one quantitative EBV-
DNA plasma assay performed after KT from January 2005
to December 2014 were included.
Data were extracted from the clinical database and from
the computerized microbiological database. Patients with
negative plasma EBV-VL were compared with patients with
positive EBV-VL (any titer). In addition, patients with posi-
tive EBV-VL greater than 4000 copies/mL were compared
to patientswith EBV-VL less than 4000 copies/mL.Diagnosis
of PTLDwas made according toWorld Health Organization
criteria.22 Furthermore, PTLD characteristics in cases identi-
fied in the study period were described.
Microbiological Samples
All microbiological samples were analyzed in the Micro-
biology and Virology Laboratory of the AOU Policlinico
Modena Hospital, as routine clinical practice. EBV-DNA was
detected and quantified by EBV ELITe MGB real-time poly-
merase chain reaction of ELITech Group with a threshold
of sensitivity for detection of 225 copies/mL and a linearity
range from 225 copies/mL to 22 500 000 copies/mL. CMV-
DNAwas detected and quantified by the ABBOTTRealTime
CMVassay of ABBOTT group, with a threshold of sensitiv-
ity for detection of 62 UI/mL and a linearity range from 62 to
156 000 000 UI/mL. Polyoma BK DNA was detected and
quantified by BKV ELITe MGB real-time polymerase chain
reaction of ELITech group, with a threshold of sensitivity for
detection of 140 copies/mL and a linearity range from 140 to
140 000 000 copies/mL. The tests provide an internal control
of extraction and amplification for each sample; furthermore,
a positive and a negative control are added for each session.
The laboratory regularly participates in the external quality
control QCMD for: CMV, EBV, and Polyoma-virus BK.
Data Collection
To describe patient characteristics, the following parame-
ters were recorded at the time of kidney transplantation: re-
cipient age, gender, transplant indications, copathologies,
graft and transplantation type, EBV serological status of the
recipient and of the donor, and retransplantation. Postopera-
tive data included duration of hospital stay, acute rejection,
graft survival (in months), induction andmaintenance immu-
nosuppressive regimen, cause of death, date of death, diagno-
sis of PTLD, PTLD type, and PTLD date of diagnosis. In
addition, the following data at the time of EBV-VL sampling
were recorded: date of EBV-VL sample, presence of symp-
toms usually correlated with PTLD at the time of EBV-VL
sample or at PTLDdiagnosis, CMVor BK positivity, ongoing
2 Transplantation DIRECT ■ 2017 www.transplantationdirect.com
immunosuppressive therapy, and creatinine (mg/dL). Poten-
tial factors associated with positive EBV-VL (any titer) or
EBV-VL greater than 4000 copies/mL or PTLD were age, sex,
creatinine value (mg/dL), EBV serostatus, the use of basiliximab
versus thymoglobulin, and the use of all different immunosup-
pressive drugs.
Statistical Methods
Continuous variables were presented with mean (SD) or
median (interquartile range [IQR]), respectively, if with nor-
mal or not normal distribution. Categorical variables were
presented with frequencies (percentages). Comparisons be-
tween patients with and patients without EBV-VL positivity
were analyzed with t test, Wilcoxon (Mann-Whitney) U test,
χ2 test or Fisher exact test when appropriate. The analysis of
incidence was conducted by the method of Poisson. Univari-
ate Poisson regression analyses were carried out to assess the
risk factors associated with positive EBV-VL (any titer),
EBV-VL greater than 4000 copies/mL, and PTLD, respec-
tively. The level of statistical significance was fixed for an α
error of 0.5. The analysis has been conducted using the soft-
ware package STATA 13.1 for Mac (StataCorp ltd., College
Station, TX).
Ethical Approval
An approval from the Modena ethical committee was
obtained (Approval Number 131/15, 10/06/2015). Due to
the retrospective nature of this study the need for informed
consent was waived.
KT Patient Cohort Follow-Up
After transplantation, the patients were evaluated as out-
patients 2 times a week for the first month, once a week until
the thirdmonth, once every 2weeks up to 6months and once
a month from 6 months up to the end of the year. After
1 year, patients were evaluated every 2months, withmonthly
blood exams. In our center, EBV-VL assay was performed in
high-risk patients in the first year after transplant, in case of
signs and symptoms suggesting EBV-related disease or pri-
mary infection (fever, cytopenia, night sweats, and lymph-
adenopathy), or in patients considered at major risk of viral
reactivation by the clinicians (eg, increased immunosuppres-
sion, human immunodeficiency virus, and so on). Samples of
patients with EBV-VL persistently superior to 4000 copies/mL
despite the reduction of immunosuppressive medication were
sent to the Laboratory of Transplant Immunology and Pediat-
ric Hematology/Oncology, Fondazione IRCCS Policlinico S.
Matteo, University of Pavia, Italy, to evaluate Tcell-specific re-
sponse using ELISpot method.23 If Tcell-specific response was
absent,23 EBV-specific cytotoxic T lymphocytes (CTL)24 were
prepared and given to the patient.
RESULTS
Five hundred twenty-three patients, corresponding to
4175.3 person year follow-up (PYFU), received a kidney
transplant between 1987 and 2014 and were followed in
the Clinic of Nephrology at AOU PoliclinicoModena Hospital
after transplantation. The median follow-up post-KT was
94.6 months (IQR, 55-148). All recipients were adults with a
median age of 46 years (IQR, 35-57).Of these, 340 (65.0%) pa-
tients were men. Forty-four (8.4%) patients had a living-donor
transplant, 21 patients (4.0%) a combined kidney-liver trans-
plant and 22 patients (4.2%) a combined pancreas-kidney
transplant. Two hundred sixty-five (50.7%) transplants were
performed in Modena. The other transplants were performed
in other Italian centers.
During the entire 10-year follow-up period, 796 samples
were tested for EBV viremia. Total numbers of patients
screened for EBV-VL were 190 (36.3%) of 523, correspond-
ing to 1768.8 PYFU. Sixty-four (33.7%) of 190 patients had
EBV-VL performed in the first year after transplant, 71
(37.4%) of 190 patients had EBV-VL performed because
they had at least 1 symptom suggestive for EBV reactivation
or primary infection.
We could collect EBV serology data in 105 (55.3%) of
190 patients. Among patients for whom EBV serology data
were not available, 31 (36.5%) patients were transplanted
before 2000. Only 8 (7.6%) of 105 patients had a negative
pre-KT EBV serology. The median age of EBV-seronegative
patients was 42 years (range, 21-51). One hundred twenty-
eight (67.4%) of 190 tested patients presented at least one
positive sample for EBV. The median time between KT and
the first sample tested for EBV-VL was 1548 days (IQR,
253-4204). Figure 1 shows the flowchart of the study.
Table 1 describes patient characteristics in EBV-DNA pos-
itive and EBV-DNA negative patients.
In EBV-DNA positive patients, the median EBV-VL at
the first available evaluation was 319.5 copies/mL (IQR,
114-1070).
We found statistically significant differences between EBV-
positive and EBV-negative patients for the percentage of
retransplant (4.69 vs 0.50, P = 0.003), time between KT
and graft failure (1834 vs 522, p 0.029), mortality (6.25 vs
16.12%, P = 0.036), and number of samples tested for
EBV-VL (2 vs 1, P < 0.001). Table 2 shows the results of uni-
variate Poisson regression analysis for factors associated with
EBV-DNA positivity. Older age, the use of sirolimus, everoli-
mus, and steroids were factors associated with EBV-DNA
positivity in the univariate analysis.
Fifty-one patients presented persistent viremia with at least
2 EBV-positive sample (median, 4; range, 2-66). The median
age of patients with persistent viremia was 44 years (IQR,
33-51). Two (3.9%) of 51 patients experienced PTLD. Two
patients (3.9%) had an induction therapy with thymoglobulin,
27 (52.9%)with basiliximab or daclizumab, and 22 (43.1%)
had missing data about induction therapy. One patient
(2.0%) died.
Nineteen (14.8%) of 128 patients had at least one EBV-VL
superior to 4000 copies/mL. Incidence rate of EBV greater
than 4000 copies/mL was 1.07/100 PYFU (95% confidence
interval [CI], 0.65-1.68). The characteristics of patients with
EBV-VL greater than 4000 copies/mL and EBV-VL less than
4000 copies/mL were compared (Table 3). There were no
statistically significant differences.
Table 4 shows the results of univariate Poisson regression
analysis for factors associated with EBV-VL greater than
4000 copies/mL. The use of micofenolic acid (MPA) and ste-
roidswere associatedwithEBV-VLsuperior to4000copies/mL
in the univariate analysis.
To avoid the development of PTLD in patients with signif-
icant EBV-VL, different preemptive strategies were used: 13
(68.4%) of 19 patients had an EBV-VL follow-up in two
weeks, five patients (26.3%) had a reduction of the immuno-
suppressive regimen, six patients (31.6%) had more tests
performed to exclude a PTLD, and in five patients (26.3%)
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Tcell-specific response was evaluated. None of them developed
a PTLD. Tcell-specific responsewas also evaluated in a patient
with early PTLD. The patient with early PTLD had EBV-
specific autologous CTLs infusions whereas the T cell specific
response of the other 5 patients was considered sufficient.
Nine (1.7%) of 523 patients developed a PTLD (Table 5).
Only one (11%) was an early PTLD case. The incidence rate
of PTLD in the KT population was 0.19/100 PYFU (95%CI,
0.09-0.37). The incidence rate of PTLD in patients tested for
EBV-VL was 0.50/100 PYFU (95% CI, 0.23-0.95). Three
(33.3%) of 9 patients had a negative EBV-VL, while the
other six had a positive EBV-VL less than 4000 copies/mL.
Table 5 describes the characteristics of patients with PTLD.
The only patient with early PTLD was a high-risk patient
and presented with bowel perforation and peritonitis
9 months after KT. The histological examination of the
perforated ileal wall showed a monomorphic posttransplant
lymphoproliferative disease consistent with diffuse B large
cells lymphoma positive for CD20/L26+, bcl2+, MUM1+,
CD30/BERH2+/− and negative for CD10−, bcl6−, and CD3−.
Two (22.2%) of 9 PTLD patients had a graft failure.
Regarding the 2 patients with graft failure, the first one
underwent renal graft biopsy for progressive worsening of
renal function in January 1999. Unfortunately, the sample
was inadequate for analysis; no biopsies were subsequently
performed. Notwithstanding the lack of histological diagnosis,
the patient was treated with a course of steroid with a
significant improvement of renal function. Based on these
findings, a diagnosis of chronic allograft failure was suggested.
In March 2007, a diagnosis of multiple myeloma stage I
was made. In October 2009, the patient experienced graft
failure with haemodialysis replacement therapy. The second
patient had a diagnosis of PTLD with a large granular
lymphocyte expansion in March 2000. In July 2009, the
patient underwent renal graft biopsy that showed acute
cellular rejection in the background of chronic allograft
failure. Treatment consisted of 3 (125 mg) boluses of steroids
and addition of sirolimus to the immunosuppressive drug
regimen. In 2011, the patient experienced graft loss with
hemodialysis replacement therapy.
Remarkably, no patients with PTLDdied. No putative risk
factors evaluated in the univariate analysis were associated
with PTLD occurrence: age (incidence rate ratio [IRR],
1.01; 95% CI, 0.96-1.06), sex (men vs women: IRR, 0.92;
95% CI, 0.23-3.69), creatinine value (IRR, 1.08; 95% CI,
0.75-1.56), and induction therapy (basiliximab/daclizumab
versus thymoglobulin IRR, IRR, 2.59; 95% CI, 0.29-23.21).
Maintenance therapy was also evaluated: cyclosporine
(IRR, 1.05; 95% CI, 0.23-4.69), sirolimus (IRR, 2.17; 95%
CI, 0.26-18.05), everolimus (IRR, 1.39; 95% CI, 0.16-11.58),
tacrolimus (IRR, 3.03; 95% CI, 0.58-15.60), and steroid
(IRR, 0.64; 95% CI, 0.15-2.89).
DISCUSSION
Our study shows that most EBV-VL assays performed in
low-risk KT patients or after the first year post-KT seem to
lack clinical significance for diagnosing PTLD. The suspicion
FIGURE 1. Study flowchart.
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driven by disease symptoms and clinician experience appears
to be the keystone for PTLD diagnosis and treatment. The
utility of routinely performing EBV-VL in adult solid organ
transplant recipients to avoid PTLD development is still de-
bated.2 Indeed, despite international guidelines2,16 suggesting
EBV-VL monitoring only in high-risk recipients, in real life,
the majority of European clinicians routinely use EBV-VL
to guide both diagnostic workup and preemptive therapy.18
In our center, EBV monitoring has been used beyond
guideline indications. In fact, more than a third of the kidney
transplant patients of our cohort had at least one quantitative
EBV-VL performed. Of note, only 7.6% of tested patients
were at high-risk for PTLD development. These findings gave
us the opportunity to discuss the usefulness of EBV-VL moni-
toring in real-life clinical practice in our center. Despite the
high number of tests performed, no patients with PTLD had
an EBV-VL superior to 4000 copies/mL, and the diagnosis
was guided mostly by clinical suspicion with no important di-
agnostic role of EBV-VL.
A limitation to this finding is that, due to the observational
study design, we are not able to assess if some preemptive
treatments performed in patients with EBV-VL persistently
superior to 4000 copies/mL avoided PTLD development be-
cause of the preemptive treatment with EBV-specific CTLs.
In our cohort, no risk factors for PTLD were identified.
This result is consistent with a recent Irish National Observa-
tional Study on PTLD in adult KT population. O'Regan and
colleagues11 identified 31 late-onset PTLD and no early-
onset PTLD in almost 2000 adult KTs. Recipient EBV status
was not found to be an independent risk factor. The popula-
tion considered in the Irish National Study was like ours, since
all patients were adult and the rate of EBV IgG positivity in the
pre-KT period was high (92.4% and 94%, respectively). They
concluded that the lack of EBV naive recipients in the study
TABLE 1.
Characteristics of EBV-DNA positive and EBV-DNA negative kidney transplant patients
EBV-DNA–positive, n = 128 EBV-DNA–negative, n = 62 P
Sex
Women, n (%) 45 (35.2) 16 (25.8) 0.246
Men, n (%) 83 (64.8) 46 (74.2)
Age: mean (SD), y 46 (±14.21) 50 (±13.41) 0.104
Acute rejection, n (%) 20 (15.6) 11 (17.7) 0.834
KT primary indication, n (%)
Glomerulonephritis 53 (41.4) 26 (41.9) 0.928
Chronic pyelonephritis 40 (31.2) 21 (33.9)
Obstructive nephropathy 13 (10.2) 7 (11.3)
Hemolytic uremic syndrome 6 (4.7) 3 (4.8)
NA 16 (12.5) 5 (8.1)
Epstein-Barr recipient serostatus, n (%)
Positive 61 (47.7) 36 (58.1) 0.302
Negative 5 (3.9) 3 (4.8)
NA 62 (48.4) 23 (37.1)
Re-KT, n (%) 6 (4.7) 2 (0.5) 0.003
HCV-positive, n (%) 9 (7.0) 5 (8.1) 0.774
HIV-positive, n (%) 5 (3.9) 3 (4.8) 0.717
Comorbidities, n (%) 93 (72.7) 39 (62.9) 0.182
Graft failure, n (%) 15 (11.7) 9 (14.5) 0.643
Time between KT and graft failure: median (IQR), d 1834 (415-4389) 522 (91-3098) 0.029
Time between KT and EBV-DNA sample: median (IQR), d 1996 (433.5-4846) 718 (102-4016) 0.064
Mortality, n (%) 8 (6.2) 10 (16.1) 0.036
CMV reactivation, n (%)
NA 38 (31.9) 15 (28.8) 0.926
Negative 73 (61.3) 34 (65.4)
Positive 8 (6.7) 3 (5.8)
Polyoma virus BK reactivation, n (%)
NA 66 (55.5) 27 (51.9) 0.825
Negative 37 (31.1) 16 (30.8)
Positive 16 (13.4) 9 (17.3)
No. samples tested for EBV-DNA, median (IQR) 2 (1-5) 1 (1-1) <0.001
Induction therapy, n (%)
Basiliximab/daclizumab 67 (52.3) 39 (62.9) 0.298
Thymoglobulin 9 (7.0) 5 (8.1)
NA 52 (40.6) 18 (29.0)
Creatinine value at EBV-DNA sample: median (IQR), mg/dL 1.67 (1.33-2.43) 1.61 (2.25-2.20) 0.437
PTLD cases, n (%) 6 (4.7) 3 (4.8) 1.000
n, number; HCV, hepatitis C virus; HIV, human immunodeficiency virus; NA, not available.
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could have contributed to the paucity of early-onset disease.
The preponderance of late-onset diseases in both studies is
the most probable explanation to the lack of significance of
the recipient EBV status as risk factor for PTLD. The percent-
age of PTLD in our population was 1.7% consistent with the
percentage reported in literature where it is described a
posttransplant PTLD risk between 1% and 3%.2,11,14
Concerning EBV-DNA positivity, 67.4% of our population
had at least 1 EBV positivity.Morton et al25 showed EBV-DNA
positivity up to 46% in renal transplant recipients, using a cutoff
of 1000 copies/mL. Since we used a different cutoff (225 copies/
mL), this could explain the difference between the 2 percent-
ages. Kanakry et al20 showed that EBV-DNAwas detected in
the plasma and/or peripheral bloodmononuclear cells in the ab-
sence of EBVdisease in 25%of transplant patientswith a cutoff
of 50 copies/mL but transplant type were not described.
The percentage of retransplant was higher in EBV-positive
patients than in EBV-negative patients, because retransplant
is a known risk factor for an increased immunosuppression.
An elevated age and the use of mTORi resulted as risk fac-
tors associated with EBV positivity in the univariate analysis.
TABLE 3.
Characteristics of patients with EBV-VL >4000 and <4000 copies/mL
EBV-VL > 4000 copies/mL (n = 19) EBV-VL < 4000 copies/ml N = 109 p value
Sex
Women, n (%) 6 (31.6) 39 (35.8) 0.800
Men, n (%) 13 (68.4) 70 (64.2)
Age: mean (SD), y 46 (±13.81) 46 (±14.33) 0.842
Acute rejection, n (%) 5 (26.3) 15 (13.8) 0.177
KT primary indication, n (%)
Glomerulonephritis 9 (47.4) 44 (40.4) 0.337
Chronic pyelonephritis 6 (31.6) 34 (31.2)
Obstructive nephropathy 3 (15.8) 10 (9.2)
Hemolytic uremic syndrome 1 (5.3) 5 (4.6)
Unknown 0 (0) 16 (14.7)
Epstein-Barr recipient serostatus, n (%) 0.752
Positive 8 (42.1) 53 (48.6)
Negative 1 (5.3) 4 (3.7)
NA 10 (52.6) 52 (47.7)
Re-KT, n (%) 1 (5.3) 5 (4.6) 1.000
HCV-positive, n (%) 1 (5.3) 8 (7.3) 1.000
HIV-positive, n (%) 2 (10.5) 3 (2.7) 0.158
Comorbidities, n (%) 11 (57.9) 82 (75.2) 0.161
Graft failure, n (%) 3 (15.8) 12 (11.0) 0.466
Time between KT and graft failure, median (IQR), days 11.98 (4.21-17.51) 8.30 (4.85-14.77) 0.405
Mortality, n (%) 3 (15.8) 5 (4.6) 0.096
CMV reactivation, n (%) 1 (5.3) 7 (6.4) 1.000
Polyoma virus BK reactivation, n (%) 3 (15.8) 13 (12.0) 0.706
No. samples tested for EBV-VL, median (IQR) 7 (2-32) 2 (1-4) 0.058
Induction therapy, n (%) 0.923
Basiliximab/Daclizumab 11 (57.9) 56 (51.4)
Thymoglobulin 1 (5.3) 8 (7.3)
Unknown 7 (36.8) 45 (41.3)
Creatinine value at EBV-VL sampling, median (IQR), mg/dL 2.28 (2.53-3.27) 1.625 (1.32-1.28) 0.199
Creatinine value at day +30 from EBV-VL sample, median (IQR) (mg/dL) 1.83 (1.28 2.17) 1.59 (1.32-1.98) 0.288
Time between KT and first EBV sample, median (IQR), days 1969 (256-4821) 1828 (438-4338) 0.803
Time between KT and positive EBV-VL, median (IQR), days 1840 (523-4338) 1828 (438-4338) 0.803
PTLD cases, n (%) 0 (0) 6 (5.50) 0.593
TABLE 2.
Univariate Poisson regression analysis for factors associated
with EBV-DNA positivity (n = 190 patients)
Variables IRR 95% CI P
Age, y 1.03 1.02-1.04 <0.001
Men 1.13 0.81-1.58 0.471
Creatinine value, mg/dL 0.97 0.88-1.06 0.520
Basiliximab vs thymoglobulina 1.26 0.65-2.43 0.489
Cyclosporineb 1.35 0.97-1.89 0.075
MPAb 1.31 0.89-1.93 0.166
Sirolimusb 1.99 1.18-3.35 0.009
Everolimusb 2.42 1.62-3.60 <0.001
Tacrolimusb 1.47 0.97-2.22 0.068
Steroidsb 1.86 1.27-2.73 <0.001
Azathioprineb 0.85 0.42-1.75 0.674
IgG EBV
Positive vs negative + NA 1.54 0.71-3.37 0.270
a 120 patients.
b 171 patients.
6 Transplantation DIRECT ■ 2017 www.transplantationdirect.com
If the association with an elevated age was expected, the use
of mTORi as a risk factor for a viral reactivation was a little
bit unexpected since literature data consider its use protective
for viral reactivations and infections, in particular regarding
CMVand human herpes virus 8.26-28 Sirolimus for example
has immunostimulatory effects on the generation of memory
virus-specific CD8 T cells and this molecular pathway can
represent a significant barrier against viral infection.29 The
protective role of mTORi regarding EBV is less clear in liter-
ature. Regarding PTLD, in vitro studies showed that the
mTORi might exert a protective effect against PTLD both
by suppressing growth of cells derived from PTLD at
allograft-protecting doses30 and by inhibiting the IL-10 sig-
nal transduction pathway and the growth of EBV B cell lym-
phomas.31 On the contrary, different in vivo studies28
showed no reduction in PTLD development in mTORi use.
The use of MPA resulted as a risk factor for EBV reactiva-
tion with EBV-VL superior to 4000 copies/mL and these data
are consistent with the literature.32
This study has several methodological limitations. First,
due to the retrospective, observational, single-center study
design, and the long observation period, some data consid-
ered relevant as risk factors for EBV reactivation and PTLD
were lacking. We were not able to compare the 190 included
patients to the rest of the whole cohort. Furthermore, in a
consistent number of patients, the pretransplant EBV serol-
ogy was not available. In our clinic, the pretransplant serol-
ogy protocol is active since 2000 and 47 (24.74%) of
190 patients were transplanted before 2000 when EBV serol-
ogy data were not available. Second, we included in the anal-
ysis only patients that were evaluated an EBV-VL in the
posttransplant period at least once (36% of the total KT
cohort). As mentioned before, in our center, EBV-VL assay
is usually performed in high-risk patients, in case of signs
and symptoms suggestive for EBV-related disease or primary
infection, and in patients considered at risk for viral reactiva-
tion. For this reason, the analyzed population is probably not
representative of the entire cohort, having a higher percentage
TABLE 4.
Univariate Poisson regression analysis for factors associated
with EBV-VL >4000 copies/mL (n = 128 patients)
Variables IRR 95% CI P
Age, per 1 y 1.01 0.98-1.04 0.460
Men 1.17 0.45-3.09 0.740
Creatinine, mg/dL 1.05 0.84-1.30 0.653
Induction:
ATG vs BAS 0.46 0.06-3.58 0.460
Missinga vs BAS 0.34 0.13-1.02 0.062
CSAb 2.34 0.86-6.33 0.094
MPAc 3.03 1.15-7.97 0.024
SIRd 0.71 0.09-5.40 0.747
EVRd 2.84 1.00-8.06 0.050
TACd 1.00 0.23-4.41 0.990
Steroidsd 3.77 1.08-13.12 0.037
ATG, antithymocyte thymoglobulin; BAS, basiliximab; CSA, cyclosporine; EVR, everolimus; SIR,
sirolimus; AZA, azathioprine; TAC, tacrolimus.
a 60 patients presented missing data on induction therapy.
b 119 patients.
c 114 patients.
d 115 patients.
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of some characteristics (eg, retransplantation and acute rejec-
tion). However, no cases of PTLD were found in the nontested
population, once more suggesting that the monitoring based on
clinical suspicionmay be sufficient to screen patients. Third, our
cohortwas relatively small to describe PTLDevents.Our results
necessitate further studies with a larger sample size.
In conclusion, our data confirm that although post-
transplant lymphoproliferative disorder is one of the most
devastating complications of organ transplantation, renal
transplant recipients are at relatively low risk for PTLD.
Our study suggests that, in linewith guidelines, EBV-VL assays
may be avoided in low-risk patients/period in the absence of a
strong clinical PTLD suspicion without increasing patients'
risk of developing the disease. This represents a safe and
cost-saving clinical strategy for our center.
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